CassandraBio
Pipeline dossier

NIH & clinical-trial pipeline signals for Lantheus Holdings, Inc. (LNTH)

Leading indicators across the NIH grant → clinical trial → SEC filing chain for LNTH, mapped to public ticker LNTH (CIK 0001521036). Sourced live from public data.

⚠ Research/informational signals from public data (NIH · ClinicalTrials.gov · SEC EDGAR). Not investment advice. Full scope →
Trial → FilingLNTH35% conf

Lantheus Holdings, Inc. (LNTH) — PHASE3 protocol updated 11 days ago

Upstream (observed)
Clinical trial status (PHASE3) — [18F]PI-2620 Phase 3 Histopathological Study
↓ Phase-transition base rate 57% (Wong/Siah/Lo 2019)
Predicted downstream
SEC 8-K / press release on NDA/BLA filing (FDA submission) (12-24 mo, base rate 57%)
trial ↗filings ↗

Recent SEC 8-K filings

JSON API for this entity →